MiMedx Group Inc MDXG:NASDAQ

Last Price$3.52Cboe Real-Time Last Sale as of 3:35PM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(2.49%)
Bid (Size)$3.50 (2,200)
Ask (Size)$3.54 (5)
Day Low / High$3.43 - 3.75
Volume248.6 K

MiMedx Lifts Adjusted Net Sales Outlook for FY21

7:54AM ET 12/07/2021 MT Newswires
MiMedx Group, Inc (MDXG) said Tuesday it now expects adjusted net sales for the fiscal year 2021 to be between $253 million and $258 million, higher than the previously forecast of between $245 million and $255 million.

The revised outlook compares with the Capital IQ estimate for $253.6 million.

The forecast includes $16.7 million of Section 351 products sold in the US for the six months ended June 30. Section 351 of the Public Health Service Act refers to a set of products that will be regulated as biologicals. Biological products include "blood-derived products, vaccines, in-vivo diagnostic allergenic products, immunoglobulin products, products containing

cells or microorganisms, and most protein products," according to a US Food and Drug Administration document.

Adjusted net sales for the fiscal year 2020 stood at $240.5 million, which included $31.8 million of Section 351 product, the company said.